CEO buying at The Jenex (JEN)

CEO buying at The Jenex (V:JEN)

Roberto Fia, CEO and Director, acquired 4,005,398 Common Shares on a direct ownership basis at a price of $0.050 on December 1st, 2017. This represents a $200,270 investment into the company's shares and an account share holdings change of 66.6%.

The Jenex is in the Advanced Medical Equipment & Technology Sub Industry Group under the Healthcare Sector.

The Jenex Corporation is a medical technology company. The Company focuses on providing consumers with dermatological products in the medical device field. The Company is engaged in developing thermal therapy technology that provides topical relief to skin irritations resulting from insect bites, stings and prevention of cold sores. The Company offers a product, InterceptCS, which is a cold sore prevention device delivering localized heat and light to inactivate the cold sore virus. The InterceptCS helps in preventing cold sore outbreaks. The InterceptCS system provides controlled topical heat without the risk of burning the skin. The InterceptCS cold sore prevention system consists of an ergonomically designed hand held unit and a disposable treatment activator. It also offers, TherOZap, which is a thermal therapy insect device. The TherOZap thermal therapy reduces the inflammatory response, relieving the symptoms of pain, itch and inflammation associated with bites and stings.